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One of the most important objectives in the treatment of atrial fibrillation (AF) is the safe and 
effective prevention of thromboembolic stroke.  Allmajor society AF guidelines expend 
substantial energy on the provision of clear recommendations for the use of oral anticoagulants in 
stroke prevention.1    Because oral anticoagulants increase bleeding risk, their use is generally not 
recommended for patients at the lowest risk for stroke, with the logical (but not really proven) 
assumption that the potential risks outweigh the gains in such individuals. By far the most widely 
used system for estimating stroke risk in AF is the CHA2DS2-VASc score, which provides 1 
point each for Congestive heart failure, Hypertension, Diabetes, Vascular disease (1 point each if 
present; 0 if absent) and Sex category (1 if female, 0 if male); 2 points for prior Stroke/transient 
ischemic attack (TIA)/embolic event; 1 point for Age 65-74 and 2 points for age≥75.2 The 
Canadian Cardiovascular Society (CCS) uses a similar but somewhat different system, often 
called “CHADS-65”, with anticoagulation recommended for any of the classical CHADS2 risk 
factors (congestive heart failure, hypertension, diabetes and stroke/TIA/embolism) or for 
age≥65.3 This system was introduced in 20144 and first referred to as “CHADS-65” in the 2016 
CCS  AF Guidelines Update.5  
 
For the lowest-risk patients, none of the major societies recommend oral anticoagulation. For 
high-risk patients, there is similar congruity among all societies in recommending oral 
anticoagulation. The greatest differences among guidelines occurs for patients with low but not 
lowest risk. For patients with one CHA2DS2-VASc factor (besides sex category, which is now 
accepted to constitute a risk modifier, rather than a risk factor per se),6 the European Society of 
Cardiology (ESC) and the 2019 focused update of the Am rican Heart Association/American 
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anticoagulation may be considered.7,8 The CCS recommends anticoagulation for age≥65 and any 
of the CHADS2 factors, but not for vascular disease alone (CHADS-65; essentially CHA2DS2 
without vascular disease or female sex).3-5   
 
In this issue of the Canadian Journal of Cardiology, Glowicki et al report the results of a 
systematic approach to examining the thromboembolic risk profile in patients with one additional 
CHA2DS2-VASc risk factor (beyond sex).
9 They systematically measured important 
prothrombotic indices in AF patients, comparing the results in 52 patients with a CHA2DS2-
VASc score of 0 in men or 1 in women with those in 118 individuals with a CHA2DS2-VASc 
score of 1 in men or 2 in women. The measures that they examined include plasma clot 
permeability (Ks), clot lysis time (CLT) and endogenous thrombin potential (ETP), along with a 
range of plasma biomarkers including van Willebrand’s factor (vWF) and plasminogen-activator 
inhibitor-1 (PAI-1). Ks is a measure of fibrin clot structure. Lower values r flect more compact 
fibrin clots, and are associated with increased risk of both major bleeding and stroke/TIA.10 CLT 
quantifies the resistance of clots to breakdown in the blood, with longer CLT being associated 
with cardiovascular disease and risk factors.11 ETP is an index of the thrombin-generating ability 
resulting from the balance between coagulation-promoting and -inhibiting factors in the blood.12 
Thus, greater thrombotic risk is associated with lower values of Ks and higher values of CLT and 
ETP. 
 
Glowicki et al find an increased thrombogenic profile in patients with a single non-sex 
CHA2DS2-VASc score risk factor (i.e. score of 1 in men or 2 in women) - they have smaller 
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vWF and PAI-1, compared to those with lower CHA2DS2-VASc scores. They then go on to 
examine individual CHA2DS2-VaSc risk factors to determine their specific relationship with 
thrombotic risk. Of the CHA2DS2-VASc factors, in the optimized multivariate model only age 
65-74 was a significant determinant of all thrombotic indices: 65-74-year olds displayed smaller 
Ks and larger CLT and ETP values than younger individuals. Of the other risk factors, 
hypertension and heart failure patients had lower Ks and higher CLT values than those without; 
neither were significantly associated with ETP. Vascular disease, diabetes and sex were not 
significant determinants of any of the thrombotic indices in the multivariate model.  When each 
factor was considered alone, patients with diabetes had lower Ks values than those without, but 
there were no differences in any of the variables for those with versus without vascular disease, 
or for males versus females. 
 
These findings suggest that patients with CHA2DS2-VASc score of 1 in men or 2 in women have 
increased values of all thrombotic indices compared to those at low risk, consistent with the 
notion that the CHA2DS2-VASc score is a good measure of thrombogenic potential i  AF 
patients. On the other hand, they do not suggest a significant prothrombotic predisposition in 
patients with vascular disease or female sex, while emphasizing the important thrombotic risk 
associated with age 65-74. These results evoke the CHADS-65 approach of the CCS, including 
age 65-74 years as a key determinant of thrombotic risk while de-emphasizing sex and vascular 
disease. 
 
Stroke risk estimation algorithms and guidelines must be based on hard clinical outcome data that 
require large clinical trials and database analyses, not on thrombogenic indices (even though 
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measures data in the Glowicki study and the components of stroke-risk prediction algorithms are 
striking. A recent study analyzing extensive results from clinical trials suggested that biomarker 
data have the potential to improve stroke risk prediction,14 although the added value of 
considering biomarkers is less clear for “real-world data”.15 The results of the Glowicki report 
raise the interesting possibility that direct measure  of prothrombotic indices might be useful in 
further refining and defining the risk of thromboembolic events in AF patients. 
 
Current stroke risk stratification schemes do not iclude all stroke risk factors and are meant to be 
reductionist, aiding clinical and practical decision-making on whether or not oral anticoagulation 
is indicated.  Thus, the default position is to offer stroke prevention unless patients are at truly 
low risk, and the recent 2018 CHEST guidelines recommend initial focus on identifying “low 
risk” patients first rather than our current obsession with identifying high risk patients, whether 
clinically or with biomarkers.16 Both CHA2DS2-VASc and CHADS-65 are useful in this regard. 
The Glowicki study provides results for meaningful thrombotic indices in a substantial (albeit 
moderate) number of patients that are consistent with the higher-risk identification of individuals 
with a single non-sex CHA2DS2-VASc score risk factor. Their findings point to the dominant role 
of age 65-74 in this characterization and fail to identify a contribution of vascular disease or sex 
to prothrombotic profile, thus providing support to the approach of CHADS-65. 
 
 
Supported by the Canadian Institutes of Health Research and the Heart and Stroke Foundation of 
Canada. 
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